Up-regulation of long non-coding RNA BCAR4 predicts a poor prognosis in patients with osteosarcoma, and promotes cell invasion and metastasis.
The long non-coding RNA BCAR4 (BCAR4) has been reported to be associated with cancer development. The aim of our study was to investigate the expression of BCAR4 in osteosarcoma patients and its association with clinicopathologic parameters and the prognosis. Quantitative RT-PCR (qRT-PCR) assay was used to detect the expression of BCAR4 and its correlations with clinicopathological factors were statistically analyzed. The clinical and prognostic significance of BCAR4 expression was analyzed statistically by Kaplan-Meier estimate and Cox regression model. Furthermore, Cell proliferation, migration, and invasion were evaluated using counting assay Kit-8 (CCK-8) and transwell assay, respectively. We found that BCAR4 expression was higher in osteosarcoma tissues and cell lines than that in normal controls. The BCAR4 levels were significantly correlated with clinical stage and distant metastasis. Kaplan-Meier analysis with the log-rank test indicated that high expression of BCAR4 had a decreased overall survival (OS). Univariate and multivariate analyses showed that BCAR4 expression was an independent predictor of overall survival. Furthermore, decreased expression of BCAR4 markedly inhibited osteosarcoma cell proliferation, migration, and invasion. The results of the present study identified a crucial tumor promotive role of BCAR4 in the progression of osteosarcoma, and suggested that BCAR4 may be a potential therapeutic agent for the treatment of osteosarcoma.